BioCentury | Nov 21, 2016
Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
BioCentury | Mar 21, 2016
Product Development

Korea rising

The Korean biopharma industry is mainly known for biosimilars and me-too products. But a cohort of innovator biotechs in Korea is coming of age, bolstered by an infusion of cash from the government and by...
BC Week In Review | Jan 14, 2013
Clinical News

CG400549: Phase IIa data

Top-line data from an open-label Phase IIa trial in patients with cABSSSI due to methicillin-resistant Staphylococcus aureus (MRSA) showed that 90.9% of patients receiving once-daily CG400549 for 10-14 days were stable or improving as determined...
BC Week In Review | May 7, 2012
Clinical News

CG400549: Phase II start

This month, CrystalGenomics will begin an open-label, U.S. Phase II trial to evaluate once-daily CG400549 for 10-14 days in patients with cABSSSI due to methicillin-resistant Staphylococcus aureus (MRSA). CrystalGenomics Inc. (KOSDAQ:083790), Seongnam, South Korea  ...
BC Week In Review | May 17, 2010
Clinical News

CG400549: Phase I data

In a European Phase I trial in 42 healthy volunteers, single-ascending doses of oral CG400549 were well tolerated with no drug-related adverse events reported. The company plans to start a Phase I trial in 24...
Items per page:
1 - 5 of 5